CAR T-Cell Therapy for Non-Hodgkin's lymphoma- - Pipeline Insight, 2024

This “CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Understanding

CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma: Overview

Non-Hodgkin’s lymphoma or only lymphomas originate in the lymphatic system and spread throughout the body. Lymphomas can affect any part where lymph tissues are found. The major sites include lymph nodes, spleen, thymus, bone marrow, adenoids, and tonsils. Exposure to chemicals, infection especially with HIV, or Helicobacter pylori, and excessive usage of immunosuppressant drugs can raise the risk for non-Hodgkin’s lymphoma. Lymphomas can be treated by various ways however, CAR T-Cell therapy is a novel therapy which make use of genetically engineered T cell to make chimeric antigen protein which in turn identify the target protein on cancerous cells and kill them. CAR T-cell treatments for Non-Hodgkin’s lymphoma target a protein called CD-19, present on the surface of Non-Hodgkin’s lymphoma cells but not on healthy cells.

CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma pipeline landscape is provided which includes the disease overview and CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma treatment guidelines. The assessment part of the report embraces, in depth CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve CAR T-Cell Therapy for Multiple Myeloma.

CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Emerging Drugs Chapters

This segment of the CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Emerging Drugs

JCAR017: Juno Therapeutics Juno’s drug candidate, JCAR017, is in its phase I/II trials. The drug is in development for the treatment of Non-Hodgkin’s Lymphoma. It has been designated as an orphan drug. The drug molecule has demonstrated good safety and efficacy in its phase I trial.

CB010: Caribou Biosciences Caribou’s drug CB010 is currently being evaluated for the treatment of CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma. The drug is in phase I trial and is from the class CAR-T cell therapies which make use of altered T cell for the treatment oflymphomas.

CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different CAR T-Cell Therapy for Non-Hodgkin’s Lymphomadrugs segregated based on following parameters that define the scope of the report, such as:

Major Players in CAR T-Cell Therapy for Non-Hodgkins Lymphoma

There are approx. 5+ key companies which are developing the therapies for CAR T-Cell Therapy for Multiple Myeloma. The companies which have their CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma drug candidates in the late to mid stages and early stages, i.e. phase I/II include, Juno Therapeutics and others.

Phases

This report covers around 5+ products under different phases of clinical development like

• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as - Subcutaneous

• Intravenous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma drugs.

CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Report Insights

• CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma drugs?
• How many CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Juno Therapeutics
• Caribou Biosciences
• Allogene Therapeutics

Key Products

• JCAR017
• CB010
• ALLO501A

This product will be delivered within 2 business days.